for females ages 18-48 (full criteria)
healthy people welcome
at San Francisco, California and other locations
study started
estimated completion
Mary Norton



This multi-center prospective observational study is designed to track birth outcomes and perinatal correlates to the Panorama prenatal screening test in the general population among ten thousand women who present clinically and elect Panorama microdeletion and aneuploidy screening as part of their routine care. The primary objective is to evaluate the performance of Single Nucleotide Polymorphism (SNP)-based Non Invasive Prenatal Testing (NIPT) for 22q11.2 microdeletion (DiGeorge syndrome) in this large cohort of pregnant women. This will be done by performing a review of perinatal medical records and obtaining biospecimens after birth to perform genetic diagnostic testing for 22q11.2 deletion. Results from the follow-up specimens will be compared to those obtained by the Panorama screening test to determine test performance. Specific test performance parameters will include: PPV, specificity, and sensitivity.

Official Title

SNP-based Microdeletion and Aneuploidy RegisTry


The primary objective is to determine in a prospective study the performance of SNP based NIPT for the 22q11.2 microdeletion (DiGeorge syndrome) in a large cohort of pregnant women clinically opting for this form of screening. Specific test performance parameters will include: positive predictive value (PPV), specificity, and sensitivity.

Secondary objectives include:

  1. Determine the test performance (PPV, specificity) of SNP based NIPT for detecting other microdeletion syndromes available in the Panorama microdeletion panel (e.g., 1p36 deletion, Cri-du-chat, Prader-Willi, and Angelman) individually and all combined (including 22q11.2). Given the incidences of <1:5000, the confidence intervals are expected to be large.
  2. Determine the failure ('no call') rate for the Next-generation Aneuploidy Test Using SNPs (NATUS) method for 22q11.2 detection, as well as for aneuploidy.
  3. Determine whether a more precise risk for aneuploidy can be generated in the setting of low fetal fraction by incorporating maternal BMI (adjusted fetal fraction percentile).
  4. Assess whether low fetal fraction is associated with specific ultrasound findings that may indicate aneuploidy (e.g. triploidy, trisomy 13 and 18).
  5. Investigate the relationship between NIPT and sonographic (nuchal translucency and anatomy survey) markers and serum markers from 1st and 2nd trimester aneuploidy screening.
  6. Determine sensitivity, specificity, and PPV for chromosomal aneuploidies and sex chromosome abnormalities.
  7. Perform detailed assessment of false positive aneuploidy samples to better understand sources of error, including placental studies to further refine issues surrounding mosaicism as NIPT represents circulating placental DNA.
  8. Investigate any relationships between circulating placental DNA (fetal fraction) or other test parameters including potential genotypic markers, and outcomes related to abnormal placentation (including but not limited to preeclampsia, small for gestational age and morbidly adherent placenta).
  9. Investigate other risk factors that may impact risk assessment for microdeletions including sonographic findings consistent with 22q11.2 (cardiac anomalies and thymus size).


22q11 Deletion SyndromeDiGeorge SyndromeTrisomy 21Trisomy 18Trisomy 13Monosomy XSex Chromosome AbnormalitiesCri-du-Chat SyndromeAngelman SyndromePrader-Willi Syndrome1p36 Deletion SyndromeMicrodeletion SyndromeAneuploidy22qNon-Invasive Prenatal ScreeningSyndromeTrisomyDown SyndromeCraniosynostosesMarfan SyndromeArachnodactylyChromosome AberrationsChromosome DisordersMonosomyTrisomy 18 SyndromeTrisomy 13 SyndromeSex Chromosome AberrationsChromosome DeletionPregnancies undergoing prenatal microdeletion screening


You can join if…

Open to females ages 18-48

  • Singleton pregnancy
  • Receiving Panorama prenatal screening test for both microdeletions (at least 22q11.2) and aneuploidy
  • Planned hospital delivery
  • Gestational age of ≥ 9 weeks, 0 days based on clinical information and evaluation.
  • Able to provide informed consent

You CAN'T join if...

  • Received results of the Panorama test prior to enrollment
  • Organ transplant recipient
  • Egg donor used


  • University of California, San Francisco
    San FranciscoCalifornia94158United States
  • University of Utah
    Salt Lake CityUtah84132United States

Lead Scientist

  • Mary Norton
    Authored (or co-authored) 125 research publications


in progress, not accepting new patients
Start Date
Completion Date
Natera, Inc.
1p36 Deletion Syndrome
Angelman Syndrome
Cri-du-chat Syndrome
Study Type
Observational [Patient Registry]
Last Updated